+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

G

Actively Recruiting

Researchers are collecting long-term clinical follow-up data on patients with multiple myeloma who previously took part in therapy studies conducted by the German-Speaking Myeloma Multicenter Group GMMG. The study focuses on tracking overall survival, progression-free survival, and follow-up time to better understand the outcomes of these patients. This national registry gathers comprehensive data from multiple centers in Germany, combining therapy study results with ongoing patient information for scientific research. This is an observational, non-interventional registry that includes retrospective and prospective data on multiple myeloma patients. It incorporates basic patient data, diagnosis details, therapies received, and long-term follow-up information. Patients are observed continuously while receiving standard care until death, loss to follow-up, or withdrawal of consent. Follow-up information is collected every six months until the first disease progression and annually thereafter, using a secure, pseudonymized database with automated data checks. Participants contribute data through routine clinical visits without receiving experimental treatments. The study measures progression-free survival at 5 years and beyond, overall survival, causes of death, and therapy-free intervals after relapse. Data collection includes regular clinical monitoring and centralized oversight to ensure accuracy. This registry supports ongoing research by providing detailed long-term outcome data for multiple myeloma patients, with no limit on sample size and participation expected to continue until the study ends in 2027.

Age: 18Years +All Genders
35 locations
S

Actively Recruiting

Researchers are evaluating the impact of two different default dialysate sodium concentrations on major cardiovascular events and death in adults receiving maintenance haemodialysis for end-stage kidney disease. This pragmatic, cluster-randomised, open-label Phase 4 study compares sodium levels of 137 mmoll and 140 mmoll in real-world dialysis settings across multiple sites globally. Dialysis sites will be randomly assigned to use either a default dialysate sodium concentration of 137 mmoll or 140 mmoll for at least 90% of dialysis sessions. Other aspects of patient care will follow standard local practices. Sites must consent to participate, and individual patients will provide waiver or opt-out consent. The study expects to enroll sites over 5 to 7 years, with each participant followed for approximately 2 to 5 years until the study endpoints are reached. Participants will receive dialysis at their assigned sites with the designated sodium concentration. Researchers will monitor the time to first occurrence of major cardiovascular events or death as the primary outcome. Secondary outcomes include other cardiovascular events and individual components of the composite outcomes. Data collection and patient monitoring will continue throughout the study period, estimated to last around five years per participant.

Age: 18Years +All GendersPhase 4
264 locations